|View printer-friendly version|
|Cutera Reports Third Quarter 2013 Results|
"To improve upon our recent performance, we made a structural change to our podiatry sales organization and integrated these sales representatives with our aesthetic sales group. We are exploring options to capture a greater portion of this market with our GenesisPlus product. We had a management change in the Canadian sales team recently and we are actively focusing our resources on achieving better performance metrics. Our team in
"During the quarter we established a North American sales specialist function, initially for our ExcelV, and we have been pleased with early results. With our expanded product portfolio and new launches planned in the near future, it is imperative that we maintain focus on each product category. We are currently expanding the specialist model to other products, where we believe additional focus can provide enhanced performance.
"We are pleased with the progress that our research and development team has made during the quarter. Regarding our truSculpt product, we launched our 16cm2 applicator, which is designed to treat smaller cosmetic areas. The early feedback has been very positive, as our key competitors have been unable to provide a solution for treating smaller regions. During the quarter, customers purchased this applicator with most of their truSculpt orders."
Mr. Connors concluded, "The share repurchase plan remains active with certain terms and restrictions. We remain focused on many initiatives in order to improve revenue and we expect to achieve improved gross and operating margins, as well as cash generation in the fourth quarter of 2013 and beyond."
The conference call to discuss these results is scheduled to begin at
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning